VRTX - Vertex Pharmaceuticals Inc Stock Analysis
Vertex Pharmaceuticals Inc (VRTX) is a publicly traded company listed on the . It operates in the industry, part of the broader sector. The company has a market capitalization of 134.06B, generates annual revenue of 12.70B, and reports net income of 4.41B. As of the latest data, the stock is trading at 528.90 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.06), indicating current market sentiment. Institutional ownership is reported at 98.19%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 33.81%, trading within a 52-week range of 374.17 - 560.25.
VRTX - Vertex Pharmaceuticals Inc
528.90
Analyst Consensus
Buy 4.06
VRTX – Analyst Rating Summary
- Strong Buy: 11
- Buy: 18
- Hold: 6
- Sell: 0
- Strong Sell: 1
- Total Analysts: 36
| Index: | NDX, S&P 500 | P/E: | 30.77 | EPS (ttm): | 17.19 | Insider Own: | 0.22% | Shs Outstand: | 253.35M | Perf Week: | -2.87% |
| Market Cap: | 134.06B | Forward P/E: | 24.96 | EPS next Y: | 21.19 | Insider Trans: | -5.45% | Shs Float: | 252.89M | Perf Month: | 6.62% |
| Income(ttm): | 4.41B | PEG: | 2.22 | EPS next Q: | 4.80 | Inst Own: | 98.19% | Short Float: | 1.64% | Perf Quarter: | 19.40% |
| Revenue(ttm): | 12.70B | P/S: | 10.56 | EPS this Y: | 1.92% | Inst Trans: | 0.13% | Short Ratio: | 2.80 | Perf Half Y: | 14.76% |
| Book/sh: | 79.92 | P/B: | 6.62 | EPS next Y: | 12.99% | ROA: | 17.12% | Short Interest: | 4.15M | Perf Year: | 33.81% |
| Cash/sh: | 31.02 | P/C: | 17.05 | EPS next 5Y: | 11.22% | ROE: | 23.54% | 52W Range: | 374.17 - 560.25 | Perf YTD: | 16.66% |
| Dividend Est.: | - | P/FCF: | 35.31 | EPS past 3/5Y: | 6.12% 8.28% | ROIC: | 19.82% | 52W High: | 560.25 -5.60% | Beta: | 0.27 |
| Dividend TTM: | - | Quick Ratio: | 2.74 | Sales past 3/5Y: | 11.34% 14.23% | Gross Margin: | 86.12% | 52W Low: | 374.17 41.35% | Perf 5Y: | 176.38% |
| Dividend Ex-Date: | - | Current Ratio: | 3.19 | EPS Y/Y TTM: | 22.53% | Oper. Margin: | 39.54% | RSI (14): | 49.92 | Volatility: | 1.91% 2.38% |
| Employees: | 6400 | Debt/Eq: | 0.10 | Sales Y/Y TTM: | 11.45% | Profit Margin: | 34.69% | Recom: | 1.64 | Target Price: | 574.32 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.10 | EPS Q/Q: | 8.02% | Payout: | 0.00% | Rel Volume: | 0.76 | Prev Close: | 546.12 |
| Sales Surprise: | 3.20% | EPS Surprise: | -0.23% | Sales Q/Q: | 11.99% | Earnings: | Aug 03 AMC | Avg Volume: | 1.48M | Price: | 528.90 |
| SMA20: | -1.88% | SMA50: | 3.80% | SMA200: | 13.35% | Undervalued: 8.59% | Volume: | 1,121,470 | Change: | -3.15% | |
Graham Classic formula value: 477.59
(P/E=8 * 1g) Min value: 296.68
(current P/E * 2g) Max value: 821.35
Average value: 531.87
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.